Novartis announced today that Fabhalta has shown statistically significant and clinically relevant improvement in hemoglobin in a new population of patients with paroxysmal nocturnal hemoglobinuria (PNH).

According to the results of a Phase IIIB study, adult patients with PNH who switched to this oral medication showed a significant improvement in their hemoglobin (Hb) levels.

The trial was designed to evaluate Fabhalta in a population with higher baseline Hb levels than those in the pivotal Phase III program, thereby expanding the clinical data base.

The laboratory emphasizes that no treated patients required blood transfusions, experienced hemolytic crises, or suffered major adverse vascular events during the course of their treatment.

Patients also reported an average improvement in their fatigue levels, with an improvement of 4.88 points after 84 days of treatment and 4.29 points after 168 days.

HNP is a rare, chronic, and serious blood disorder that causes anemia, thrombosis (blood clots), fatigue, and other disabling symptoms.It is estimated that 10 to 20 people per million worldwide live with the disease, with diagnosis most common in adults aged 30 to 40.

Following these announcements, Novartis shares rose 0.3% on Thursday morning on the Zurich Stock Exchange, posting the strongest gain on the SMI index of leading Swiss stocks.


Copyright (c) 2025 CercleFinance.com. All rights reserved.